Calreticulin – a multifaced protein

[1] Alaiya A., Roblick U., Egevad L., Carlsson A., Franzén B., Volz D., Huwendiek S., Linder S., Auer G.: Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal. Cell. Pathol., 2000; 21: 1–9 AlaiyaA. RoblickU. EgevadL. CarlssonA. FranzénB. VolzD. HuwendiekS. LinderS. AuerG. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma Anal. Cell. Pathol. 2000 21 1 9 10.1155/2000/351963461842011254220 Search in Google Scholar

[2] Alfonso P., Núñez A., Madoz-Gurpide J., Lombardia L., Sánchez L., Casal J.I.: Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis. Proteomics, 2005; 5: 2602–2611 AlfonsoP. NúñezA. Madoz-GurpideJ. LombardiaL. SánchezL. CasalJ.I. Proteomic expression analysis of colorectal cancer by two-dimensional differential gel electrophoresis Proteomics 2005 5 2602 2611 10.1002/pmic.20040119615924290 Search in Google Scholar

[3] Araki M., Yang Y., Masubuchi N., Hironaka Y., Takei H., Morishita S., Mizukami Y., Kan S., Shirane S., Edahiro Y., Sunami Y., Ohsaka A., Komatsu N.: Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood, 2016; 127: 1307–1316 ArakiM. YangY. MasubuchiN. HironakaY. TakeiH. MorishitaS. MizukamiY. KanS. ShiraneS. EdahiroY. SunamiY. OhsakaA. KomatsuN. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms Blood 2016 127 1307 1316 10.1182/blood-2015-09-67117226817954 Search in Google Scholar

[4] Arshad N., Cresswell P.: Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I. J. Biol. Chem., 2018; 293: 9555–9569 ArshadN. CresswellP. Tumor-associated calreticulin variants functionally compromise the peptide loading complex and impair its recruitment of MHC-I J. Biol. Chem. 2018 293 9555 9569 10.1074/jbc.RA118.002836601647329769311 Search in Google Scholar

[5] Chachoua I., Pecquet C., El-Khoury M., Nivarthi H., Albu R.I., Marty C., Gryshkova V., Defour J.P., Vertenoeil G., Ngo A., Koay A., Raslova H., Courtoy P.J., Choong M.L., Plo I., et al.: Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood, 2016; 127: 1325–1335 ChachouaI. PecquetC. El-KhouryM. NivarthiH. AlbuR.I. MartyC. GryshkovaV. DefourJ.P. VertenoeilG. NgoA. KoayA. RaslovaH. CourtoyP.J. ChoongM.L. PloI. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants Blood 2016 127 1325 1335 10.1182/blood-2015-11-68193226668133 Search in Google Scholar

[6] Chahed K., Kabbage M., Ehret-Sabatier L., Lemaitre-Guillier C., Remadi S., Hoebeke J., Chouchane L.: Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: The two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses. Int. J. Oncol., 2005; 27: 1425–1431 ChahedK. KabbageM. Ehret-SabatierL. Lemaitre-GuillierC. RemadiS. HoebekeJ. ChouchaneL. Expression of fibrinogen E-fragment and fibrin E-fragment is inhibited in the human infiltrating ductal carcinoma of the breast: The two-dimensional electrophoresis and MALDI-TOF-mass spectrometry analyses Int. J. Oncol. 2005 27 1425 1431 10.3892/ijo.27.5.1425 Search in Google Scholar

[7] Chang H.H., Lee H., Hu M.K., Tsao P.N., Juan H.F., Huang M.C., Shih Y.Y., Wang B.J., Jeng Y.M., Chang C.L., Huang S.F., Tsay Y.G., Hsieh F.J., Lin K.H., Hsu W.M., et al.: Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma. Clin. Cancer Res., 2010; 16: 4411–4420 ChangH.H. LeeH. HuM.K. TsaoP.N. JuanH.F. HuangM.C. ShihY.Y. WangB.J. JengY.M. ChangC.L. HuangS.F. TsayY.G. HsiehF.J. LinK.H. HsuW.M. Notch1 expression predicts an unfavorable prognosis and serves as a therapeutic target of patients with neuroblastoma Clin. Cancer Res. 2010 16 4411 4420 10.1158/1078-0432.CCR-09-336020736329 Search in Google Scholar

[8] Chao M.P., Jaiswal S., Weissman-Tsukamoto R., Alizadeh A.A., Gentles A.J., Volkmer J., Weiskopf K., Willingham S.B., Raveh T., Park C.Y., Majeti R., Weissman I.L.: Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counter-balanced by CD47. Sci. Transl. Med., 2010; 2: 63ra94 ChaoM.P. JaiswalS. Weissman-TsukamotoR. AlizadehA.A. GentlesA.J. VolkmerJ. WeiskopfK. WillinghamS.B. RavehT. ParkC.Y. MajetiR. WeissmanI.L. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counter-balanced by CD47 Sci. Transl. Med. 2010 2 63ra94 10.1126/scitranslmed.3001375412690421178137 Search in Google Scholar

[9] Chiang W.F., Hwang T.Z., Hour T.C., Wang L.H., Chiu C.C., Chen H.R., Wu Y.J., Wang C.C., Wang L.F., Chien C.Y., Chen J.H., Hsu C.T., Chen J.Y.F.: Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma. Oral Oncol., 2013; 49: 534–541 ChiangW.F. HwangT.Z. HourT.C. WangL.H. ChiuC.C. ChenH.R. WuY.J. WangC.C. WangL.F. ChienC.Y. ChenJ.H. HsuC.T. ChenJ.Y.F. Calreticulin, an endoplasmic reticulum-resident protein, is highly expressed and essential for cell proliferation and migration in oral squamous cell carcinoma Oral Oncol. 2013 49 534 541 10.1016/j.oraloncology.2013.01.00323375593 Search in Google Scholar

[10] Cid N.D., Jeffery E., Rizvi S.M., Stamper E., Peters L.R., Brown W.C., Provoda C., Raghavan M.: Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway. J. Biol. Chem., 2010; 285: 4520–4535 CidN.D. JefferyE. RizviS.M. StamperE. PetersL.R. BrownW.C. ProvodaC. RaghavanM. Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway J. Biol. Chem. 2010 285 4520 4535 10.1074/jbc.M109.085407283605719959473 Search in Google Scholar

[11] Cockram T.O.J., Puigdellívol M., Brown G.C.: Calreticulin and galectin-3 opsonise bacteria for phagocytosis by microglia. Front. Immunol., 2019; 10: 2647 CockramT.O.J. PuigdellívolM. BrownG.C. Calreticulin and galectin-3 opsonise bacteria for phagocytosis by microglia Front. Immunol. 2019 10 2647 10.3389/fimmu.2019.02647686138131781126 Search in Google Scholar

[12] Coppolino M.G., Woodside M.J., Demaurex N., Grinstein S., St-Arnaud R., Dedhar S.: Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion. Nature, 1997; 386: 843–847 CoppolinoM.G. WoodsideM.J. DemaurexN. GrinsteinS. St-ArnaudR. DedharS. Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion Nature 1997 386 843 847 10.1038/386843a09126744 Search in Google Scholar

[13] Cordua S., Kjaer L., Skov V., Pallisgaard N., Hasselbalch H.C., Ellervik C.: Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood, 2019; 134: 469–479 CorduaS. KjaerL. SkovV. PallisgaardN. HasselbalchH.C. EllervikC. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population Blood 2019 134 469 479 10.1182/blood.201900111331217187 Search in Google Scholar

[14] Di Martino S., Crescente G., De Lucia V., Di Paolo M., Marotta G., De Lucia D., Abbadessa A.: The emerging role of calreticulin in cancer cells. World Cancer Res. J., 2017; 4: e926 Di MartinoS. CrescenteG. De LuciaV. Di PaoloM. MarottaG. De LuciaD. AbbadessaA. The emerging role of calreticulin in cancer cells World Cancer Res. J. 2017 4 e926 Search in Google Scholar

[15] Du X.L., Hu H., Lin D.C., Xia S.H., Shen X.M., Zhang Y., Luo M.L., Feng Y.B., Cai Y., Xu X., Han Y.L., Zhan Q.M., Wang M.R.: Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma. J. Mol. Med., 2007; 85: 863–875 DuX.L. HuH. LinD.C. XiaS.H. ShenX.M. ZhangY. LuoM.L. FengY.B. CaiY. XuX. HanY.L. ZhanQ.M. WangM.R. Proteomic profiling of proteins dysregulated in Chinese esophageal squamous cell carcinoma J. Mol. Med. 2007 85 863 875 10.1007/s00109-007-0159-417318615 Search in Google Scholar

[16] Eder-Azanza L., Navarro D., Aranaz P., Novo F.J., Cross N.C., Vizmanos J.L.: Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling. Leukemia, 2014; 28: 2106–2109 Eder-AzanzaL. NavarroD. AranazP. NovoF.J. CrossN.C. VizmanosJ.L. Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling Leukemia 2014 28 2106 2109 10.1038/leu.2014.19024919806 Search in Google Scholar

[17] Eggleton P., Bremer E., Dudek E., Michalak M.: Calreticulin, a therapeutic target? Expert Opin. Ther. Targets, 2016; 20: 1137–1147 EggletonP. BremerE. DudekE. MichalakM. Calreticulin, a therapeutic target? Expert Opin. Ther. Targets 2016 20 1137 1147 10.1517/14728222.2016.116469526959400 Search in Google Scholar

[18] Elf S., Abdelfattah N.S., Chen E., Perales-Patón J., Rosen E.A., Ko A., Peisker F., Florescu N., Giannini S., Wolach O., Morgan E.A., Tothova Z., Losman J.A., Schneider R.K., Al-Shahrour F., et al.: Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov., 2016; 6: 368–381 ElfS. AbdelfattahN.S. ChenE. Perales-PatónJ. RosenE.A. KoA. PeiskerF. FlorescuN. GianniniS. WolachO. MorganE.A. TothovaZ. LosmanJ.A. SchneiderR.K. Al-ShahrourF. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation Cancer Discov. 2016 6 368 381 10.1158/2159-8290.CD-15-1434485186626951227 Search in Google Scholar

[19] Falchi M., Varricchio L., Martelli F., Marra M., Picconi O., Tafuri A., Girelli G., Uversky V.N., Migliaccio A.R.: The calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera. Exp. Hematol., 2017; 50: 53–76 FalchiM. VarricchioL. MartelliF. MarraM. PicconiO. TafuriA. GirelliG. UverskyV.N. MigliaccioA.R. The calreticulin control of human stress erythropoiesis is impaired by JAK2V617F in polycythemia vera Exp. Hematol. 2017 50 53 76 10.1016/j.exphem.2017.02.001577985228232234 Search in Google Scholar

[20] Fucikova J., Becht E., Iribarren K., Goc J., Remark R., Damotte D., Alifano M., Devi P., Biton J., Germain C., Lupo A., Fridman W.H., Dieu-Nosjean M.C., Kroemer G., Sautès-Fridman C., et al.: Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res., 2016; 76: 1746–1756 FucikovaJ. BechtE. IribarrenK. GocJ. RemarkR. DamotteD. AlifanoM. DeviP. BitonJ. GermainC. LupoA. FridmanW.H. Dieu-NosjeanM.C. KroemerG. Sautès-FridmanC. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis Cancer Res. 2016 76 1746 1756 10.1158/0008-5472.CAN-15-114226842877 Search in Google Scholar

[21] Fucikova J., Kline J.P., Galluzzi L., Spisek R.: Calreticulin arms NK cells against leukemia. Oncoimmunology, 2020; 9: 1671763 FucikovaJ. KlineJ.P. GalluzziL. SpisekR. Calreticulin arms NK cells against leukemia Oncoimmunology 2020 9 1671763 10.1080/2162402X.2019.1671763695945132002282 Search in Google Scholar

[22] Fucikova J., Moserova I., Urbanova L., Bezu L., Kepp O., Cremer I., Salek C., Strnad P., Kroemer G., Galluzzi L., Spisek R.: Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front. Immunol., 2015; 6: 402 FucikovaJ. MoserovaI. UrbanovaL. BezuL. KeppO. CremerI. SalekC. StrnadP. KroemerG. GalluzziL. SpisekR. Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer Front. Immunol. 2015 6 402 10.3389/fimmu.2015.00402452828126300886 Search in Google Scholar

[23] Fucikova J., Truxova I., Hensler M., Becht E., Kasikova L., Moserova I., Vosahlikova S., Klouckova J., Church S.E., Cremer I., Kepp O., Kroemer G., Galluzzi L., Salek C., Spisek R.: Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 2016; 128: 3113–3124 FucikovaJ. TruxovaI. HenslerM. BechtE. KasikovaL. MoserovaI. VosahlikovaS. KlouckovaJ. ChurchS.E. CremerI. KeppO. KroemerG. GalluzziL. SalekC. SpisekR. Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients Blood 2016 128 3113 3124 10.1158/2326-6074.CRICIMTEATIAACR18-A072 Search in Google Scholar

[24] Galluzzi L., Buqué A., Kepp O., Zitvogel L., Kroemer G.: Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol., 2017; 17: 97–111 GalluzziL. BuquéA. KeppO. ZitvogelL. KroemerG. Immunogenic cell death in cancer and infectious disease Nat. Rev. Immunol. 2017 17 97 111 10.1038/nri.2016.10727748397 Search in Google Scholar

[25] Guo L., Nakamura K., Lynch J., Opas M., Olson E.N., Agellon L.B., Michalak M.: Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouse. J. Biol. Chem., 2002; 277: 50776–50779 GuoL. NakamuraK. LynchJ. OpasM. OlsonE.N. AgellonL.B. MichalakM. Cardiac-specific expression of calcineurin reverses embryonic lethality in calreticulin-deficient mouse J. Biol. Chem. 2002 277 50776 50779 10.1074/jbc.M20990020012377773 Search in Google Scholar

[26] Han A., Li C., Zahed T., Wong M., Smith I., Hoedel K., Green D., Boiko A.D.: Calreticulin is a critical cell survival factor in malignant neoplasms. PLoS Biol., 2019; 17: e3000402 HanA. LiC. ZahedT. WongM. SmithI. HoedelK. GreenD. BoikoA.D. Calreticulin is a critical cell survival factor in malignant neoplasms PLoS Biol. 2019 17 e3000402 10.1371/journal.pbio.3000402676845731568485 Search in Google Scholar

[27] Han L., Schubert C., Köhler J., Schemionek M., Isfort S., Brümmendorf T.H., Koschmieder S., Chatain N.: Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion. J. Hematol. Oncol., 2016; 9: 45 HanL. SchubertC. KöhlerJ. SchemionekM. IsfortS. BrümmendorfT.H. KoschmiederS. ChatainN. Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion J. Hematol. Oncol. 2016 9 45 10.1186/s13045-016-0275-0489437327177927 Search in Google Scholar

[28] Hellman K., Alaiya A.A., Schedvins K., Steinberg W., Hellström A.C., Auer G.: Protein expression patterns in primary carcinoma of the vagina. Br. J. Cancer, 2004; 91: 319–326 HellmanK. AlaiyaA.A. SchedvinsK. SteinbergW. HellströmA.C. AuerG. Protein expression patterns in primary carcinoma of the vagina Br. J. Cancer 2004 91 319 326 10.1038/sj.bjc.6601944240980715199389 Search in Google Scholar

[29] Holmström M.O., Cordua S., Skov V., Kjær L., Pallisgaard N., Ellervik C., Hasselbalch H.C., Andersen M.H.: Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer. Cancer Immunol. Immunother., 2020; 69: 315–324 HolmströmM.O. CorduaS. SkovV. KjærL. PallisgaardN. EllervikC. HasselbalchH.C. AndersenM.H. Evidence of immune elimination, immuno-editing and immune escape in patients with hematological cancer Cancer Immunol. Immunother. 2020 69 315 324 10.1007/s00262-019-02473-y31915854 Search in Google Scholar

[30] Holmström M.O., Martinenaite E., Ahmad S.M., Met Ö., Friese C., Kjær L., Riley C.H., Thor Straten P., Svane I.M., Hasselbalch H.C., Andersen M.H.: The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia, 2018; 32: 429–437 HolmströmM.O. MartinenaiteE. AhmadS.M. MetÖ. FrieseC. KjærL. RileyC.H. Thor StratenP. SvaneI.M. HasselbalchH.C. AndersenM.H. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy Leukemia 2018 32 429 437 10.1038/leu.2017.21428676668 Search in Google Scholar

[31] How J., Hobbs G.S., Mullally A.: Mutant calreticulin in myeloproliferative neoplasms. Blood, 2019; 134: 2242–2248 HowJ. HobbsG.S. MullallyA. Mutant calreticulin in myeloproliferative neoplasms Blood 2019 134 2242 2248 10.1182/blood.2019000622692366831562135 Search in Google Scholar

[32] Hsu W.M., Hsieh F.J., Jeng Y.M., Kuo M.L., Chen C.N., Lai D.M., Hsieh L.J., Wang B.T., Tsao P.N., Lee H., Lin M.T., Lai H.S., Chen W.J.: Calreticulin expression in neuroblastoma - a novel independent prognostic factor. Ann. Oncol., 2005; 16: 314–321 HsuW.M. HsiehF.J. JengY.M. KuoM.L. ChenC.N. LaiD.M. HsiehL.J. WangB.T. TsaoP.N. LeeH. LinM.T. LaiH.S. ChenW.J. Calreticulin expression in neuroblastoma - a novel independent prognostic factor Ann. Oncol. 2005 16 314 321 10.1093/annonc/mdi06215668290 Search in Google Scholar

[33] Jo S.H., Choi J.A., Lim Y.J., Lee J., Cho S.N., Oh S.M., Go D., Kim S.H., Song C.H.: Calreticulin modulates the intracellular survival of mycobacteria by regulating ER-stress-mediated apoptosis. Onco-target, 2017; 8: 58686–58698 JoS.H. ChoiJ.A. LimY.J. LeeJ. ChoS.N. OhS.M. GoD. KimS.H. SongC.H. Calreticulin modulates the intracellular survival of mycobacteria by regulating ER-stress-mediated apoptosis Onco-target 2017 8 58686 58698 10.18632/oncotarget.17419560168428938588 Search in Google Scholar

[34] Kageyama S., Isono T., Matsuda S., Ushio Y., Satomura S., Terai A., Arai Y., Kawakita M., Okada Y., Yoshiki T.: Urinary calreticulin in the diagnosis of bladder urothelial carcinoma. Int. J. Urol., 2009; 16: 481–486 KageyamaS. IsonoT. MatsudaS. UshioY. SatomuraS. TeraiA. AraiY. KawakitaM. OkadaY. YoshikiT. Urinary calreticulin in the diagnosis of bladder urothelial carcinoma Int. J. Urol. 2009 16 481 486 10.1111/j.1442-2042.2009.02287.x19389084 Search in Google Scholar

[35] Kasikova L., Hensler M., Truxova I., Skapa P., Laco J., Belicova L., Praznovec I., Vosahlikova S., Halaska M.J., Brtnicky T., Rob L., Presl J., Kostun J., Cremer I., Ryska A., et al.: Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. J. Immunother. Cancer, 2019; 7: 312 KasikovaL. HenslerM. TruxovaI. SkapaP. LacoJ. BelicovaL. PraznovecI. VosahlikovaS. HalaskaM.J. BrtnickyT. RobL. PreslJ. KostunJ. CremerI. RyskaA. Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients J. Immunother. Cancer 2019 7 312 10.1186/s40425-019-0781-z686869431747968 Search in Google Scholar

[36] Klampfl T., Gisslinger H., Harutyunyan A.S., Nivarthi H., Rumi E., Milosevic J.D., Them N.C., Berg T., Gisslinger B., Pietra D., Chen D., Vladimer G.I., Bagienski K., Milanesi C., Casetti I.C., et al.: Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med., 2013; 369: 2379–2390 KlampflT. GisslingerH. HarutyunyanA.S. NivarthiH. RumiE. MilosevicJ.D. ThemN.C. BergT. GisslingerB. PietraD. ChenD. VladimerG.I. BagienskiK. MilanesiC. CasettiI.C. Somatic mutations of calreticulin in myeloproliferative neoplasms N. Engl. J. Med. 2013 369 2379 2390 10.1056/NEJMoa131134724325356 Search in Google Scholar

[37] Limjindaporn T., Wongwiwat W., Noisakran S., Srisawat C., Netsawang J., Puttikhunt C., Kasinrerk W., Avirutnan P., Thiemmeca S., Sriburi R., Sittisombut N., Malasit P., Yenchitsomanus P.: Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus production. Biochem. Biophys. Res. Commun., 2009; 379: 196–200 LimjindapornT. WongwiwatW. NoisakranS. SrisawatC. NetsawangJ. PuttikhuntC. KasinrerkW. AvirutnanP. ThiemmecaS. SriburiR. SittisombutN. MalasitP. YenchitsomanusP. Interaction of dengue virus envelope protein with endoplasmic reticulum-resident chaperones facilitates dengue virus production Biochem. Biophys. Res. Commun. 2009 379 196 200 10.1016/j.bbrc.2008.12.07019105951 Search in Google Scholar

[38] Liu P., Zhao L., Kroemer G., Kepp O.: Secreted calreticulin mutants subvert anticancer immunosurveillance. OncoImmunology, 2019; 9: 1708126 LiuP. ZhaoL. KroemerG. KeppO. Secreted calreticulin mutants subvert anticancer immunosurveillance OncoImmunology 2019 9 1708126 10.1080/2162402X.2019.1708126695945432002304 Search in Google Scholar

[39] Liu P., Zhao L., Loos F., Marty C., Xie W., Martins I., Lachkar S., Qu B., Waeckel-Énée E., Plo I., Vainchenker W., Perez F., Rodriguez D., López-Otin C., van Endert P., et al.: Immunosuppression by mutated calreticulin released from malignant cells. Mol. Cell, 2020; 77: 748–760.e9 LiuP. ZhaoL. LoosF. MartyC. XieW. MartinsI. LachkarS. QuB. Waeckel-ÉnéeE. PloI. VainchenkerW. PerezF. RodriguezD. López-OtinC. van EndertP. Immunosuppression by mutated calreticulin released from malignant cells Mol. Cell 2020 77 748 760.e9 10.1016/j.molcel.2019.11.00431785928 Search in Google Scholar

[40] Lu Y.C., Weng W.C., Lee H.: Functional roles of calreticulin in cancer biology. Biomed. Res. Int., 2015; 2015: 526524 LuY.C. WengW.C. LeeH. Functional roles of calreticulin in cancer biology Biomed. Res. Int. 2015 2015 526524 10.1155/2015/526524439601625918716 Search in Google Scholar

[41] Lwin Z.M., Guo C., Salim A., Yip G.W., Chew F.T., Nan J., Thike A.A., Tan P.H., Bay B.H.: Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod. Pathol., 2010; 23: 1559–1566 LwinZ.M. GuoC. SalimA. YipG.W. ChewF.T. NanJ. ThikeA.A. TanP.H. BayB.H. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma Mod. Pathol. 2010 23 1559 1566 10.1038/modpathol.2010.17320834237 Search in Google Scholar

[42] Lynch J., Guo L., Gelebart P., Chilibeck K., Xu J., Molkentin J.D., Agellon L.B., Michalak M.: Calreticulin signals upstream of calcineurin and MEF2C in a critical Ca²⁺-dependent signaling cascade. J. Cell Biol., 2005; 170: 37–47 LynchJ. GuoL. GelebartP. ChilibeckK. XuJ. MolkentinJ.D. AgellonL.B. MichalakM. Calreticulin signals upstream of calcineurin and MEF2C in a critical Ca²⁺-dependent signaling cascade J. Cell Biol. 2005 170 37 47 10.1083/jcb.200412156217139215998798 Search in Google Scholar

[43] Margolin E., Oh Y.J., Verbeek M., Naude J., Ponndorf D., Mesh-cheriakova Y.A., Peyret H., van Diepen M.T., Chapman R., Meyers A.E., Lomonossoff G.P., Matoba N., Williamson A.L., Rybicki E.P.: Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants. Plant Biotechnol. J., 2020; 18: 2109–2117 MargolinE. OhY.J. VerbeekM. NaudeJ. PonndorfD. Mesh-cheriakovaY.A. PeyretH. van DiepenM.T. ChapmanR. MeyersA.E. LomonossoffG.P. MatobaN. WilliamsonA.L. RybickiE.P. Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants Plant Biotechnol. J. 2020 18 2109 2117 10.1111/pbi.13369754001432096288 Search in Google Scholar

[44] Marty C., Pecquet C., Nivarthi H., El-Khoury M., Chachoua I., Tulliez M., Villeval J.L., Raslova H., Kralovics R., Constantinescu S.N., Plo I., Vainchenker W.: Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood, 2016; 127: 1317–1324 MartyC. PecquetC. NivarthiH. El-KhouryM. ChachouaI. TulliezM. VillevalJ.L. RaslovaH. KralovicsR. ConstantinescuS.N. PloI. VainchenkerW. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis Blood 2016 127 1317 1324 10.1182/blood-2015-11-67957126608331 Search in Google Scholar

[45] Mesaeli N., Nakamura K., Zvaritch E., Dickie P., Dziak E., Krause K.H., Opas M., MacLennan D.H., Michalak M.: Calreticulin is essential for cardiac development. J. Cell Biol., 1999; 144: 857–868 MesaeliN. NakamuraK. ZvaritchE. DickieP. DziakE. KrauseK.H. OpasM. MacLennanD.H. MichalakM. Calreticulin is essential for cardiac development J. Cell Biol. 1999 144 857 868 10.1083/jcb.144.5.857214818610085286 Search in Google Scholar

[46] Michalak M., Groenendyk J., Szabo E., Gold L.I., Opas M.: Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem. J., 2009; 417: 651–666 MichalakM. GroenendykJ. SzaboE. GoldL.I. OpasM. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum Biochem. J. 2009 417 651 666 10.1042/BJ2008184719133842 Search in Google Scholar

[47] Migliaccio A.R., Uversky V.N.: Dissecting physical structure of calreticulin, an intrinsically disordered Ca²⁺-buffering chaperone from endoplasmic reticulum. J. Biomol. Struct. Dyn., 2018; 36: 1617–1636 MigliaccioA.R. UverskyV.N. Dissecting physical structure of calreticulin, an intrinsically disordered Ca²⁺-buffering chaperone from endoplasmic reticulum J. Biomol. Struct. Dyn. 2018 36 1617 1636 10.1080/07391102.2017.1330224624314328504081 Search in Google Scholar

[48] Nakamura K., Zuppini A., Arnaudeau S., Lynch J., Ahsan I., Krause R., Papp S., De Smedt H., Parys J.B., Muller-Esterl W., Lew D.P., Krause K.H., Demaurex N., Opas M., Michalak M.: Functional specialization of calreticulin domains. J. Cell Biol., 2001; 154: 961–972 NakamuraK. ZuppiniA. ArnaudeauS. LynchJ. AhsanI. KrauseR. PappS. De SmedtH. ParysJ.B. Muller-EsterlW. LewD.P. KrauseK.H. DemaurexN. OpasM. MichalakM. Functional specialization of calreticulin domains J. Cell Biol. 2001 154 961 972 10.1083/jcb.200102073219619511524434 Search in Google Scholar

[49] Nangalia J., Massie C.E., Baxter E.J., Nice F.L., Gundem G., Wedge D.C., Avezov E., Li J., Kollmann K., Kent D.G., Aziz A., Godfrey A.L., Hinton J., Martincorena I., Van Loo P., et al.: Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med., 2013; 369: 2391–2405 NangaliaJ. MassieC.E. BaxterE.J. NiceF.L. GundemG. WedgeD.C. AvezovE. LiJ. KollmannK. KentD.G. AzizA. GodfreyA.L. HintonJ. MartincorenaI. Van LooP. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 N. Engl. J. Med. 2013 369 2391 2405 10.1056/NEJMoa1312542396628024325359 Search in Google Scholar

[50] Nguyen T.O., Capra J.D., Sontheimer R.D.: Calreticulin is transcriptionally upregulated by heat shock, calcium and heavy metals. Mol. Immunol., 1996; 33: 379–386 NguyenT.O. CapraJ.D. SontheimerR.D. Calreticulin is transcriptionally upregulated by heat shock, calcium and heavy metals Mol. Immunol. 1996 33 379 386 10.1016/0161-5890(95)00149-2 Search in Google Scholar

[51] Ostwald T.J., MacLennan D.H.: Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum. J. Biol. Chem., 1974; 249: 974–979 OstwaldT.J. MacLennanD.H. Isolation of a high affinity calcium-binding protein from sarcoplasmic reticulum J. Biol. Chem. 1974 249 974 979 10.1016/S0021-9258(19)43026-3 Search in Google Scholar

[52] Païdassi H., Tacnet-Delorme P., Verneret M., Gaboriaud C., Houen G., Duus K., Ling W.L., Arlaud G.J., Frachet P.: Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J. Mol. Biol., 2011; 408: 277–290 PaïdassiH. Tacnet-DelormeP. VerneretM. GaboriaudC. HouenG. DuusK. LingW.L. ArlaudG.J. FrachetP. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition J. Mol. Biol. 2011 408 277 290 10.1016/j.jmb.2011.02.02921352829 Search in Google Scholar

[53] Papp S., Fadel M.P., Kim H., McCulloch C.A., Opas M.: Calreticulin affects fibronectin-based cell-substratum adhesion via the regulation of c-Src activity. J. Biol. Chem., 2007; 282: 16585–16598 PappS. FadelM.P. KimH. McCullochC.A. OpasM. Calreticulin affects fibronectin-based cell-substratum adhesion via the regulation of c-Src activity J. Biol. Chem. 2007 282 16585 16598 10.1074/jbc.M70101120017389592 Search in Google Scholar

[54] Park S., Huh H.J., Mun Y.C., Seong C.M., Chung W.S., Chung H.S., Huh J.: Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia. Cancer Genet., 2015; 208: 630–635 ParkS. HuhH.J. MunY.C. SeongC.M. ChungW.S. ChungH.S. HuhJ. Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia Cancer Genet. 2015 208 630 635 10.1016/j.cancergen.2015.11.00126640226 Search in Google Scholar

[55] Peng R.Q., Chen Y.B., Ding Y., Zhang R., Zhang X., Yu X.J., Zhou Z.W., Zeng Y.X., Zhang X.S.: Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J. Gastroenterol., 2010; 16: 2428–2434 PengR.Q. ChenY.B. DingY. ZhangR. ZhangX. YuX.J. ZhouZ.W. ZengY.X. ZhangX.S. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer World J. Gastroenterol. 2010 16 2428 2434 10.3748/wjg.v16.i19.2428287415020480531 Search in Google Scholar

[56] Pietra D., Rumi E., Ferretti V.V., Di Buduo C.A., Milanesi C., Cavalloni C., Sant’Antonio E., Abbonante V., Moccia F., Casetti I.C., Bellini M., Renna M.C., Roncoroni E., Fugazza E., Astori C., et al.: Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia, 2016; 30: 431–438 PietraD. RumiE. FerrettiV.V. Di BuduoC.A. MilanesiC. CavalloniC. Sant’AntonioE. AbbonanteV. MocciaF. CasettiI.C. BelliniM. RennaM.C. RoncoroniE. FugazzaE. AstoriC. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms Leukemia 2016 30 431 438 10.1038/leu.2015.277474045226449662 Search in Google Scholar

[57] Qiu Y., Lynch J., Guo L., Yatsula B., Perkins A.S., Michalak M.: Regulation of the calreticulin gene by GATA6 and Evi-1 transcription factors. Biochemistry, 2008; 47: 3697–3704 QiuY. LynchJ. GuoL. YatsulaB. PerkinsA.S. MichalakM. Regulation of the calreticulin gene by GATA6 and Evi-1 transcription factors Biochemistry 2008 47 3697 3704 10.1021/bi702524v18303859 Search in Google Scholar

[58] Saito Y., Ihara Y., Leach M.R., Cohen-Doyle M.F., Williams D.B.: Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins. EMBO J., 1999; 18: 6718–6729 SaitoY. IharaY. LeachM.R. Cohen-DoyleM.F. WilliamsD.B. Calreticulin functions in vitro as a molecular chaperone for both glycosylated and non-glycosylated proteins EMBO J. 1999 18 6718 6729 10.1093/emboj/18.23.6718117173410581245 Search in Google Scholar

[59] Schcolnik-Cabrera A., Oldak B., Juárez M., Cruz-Rivera M., Flisser A., Mendlovic F.: Calreticulin in phagocytosis and cancer: Opposite roles in immune response outcomes. Apoptosis, 2019; 24: 245–255 Schcolnik-CabreraA. OldakB. JuárezM. Cruz-RiveraM. FlisserA. MendlovicF. Calreticulin in phagocytosis and cancer: Opposite roles in immune response outcomes Apoptosis 2019 24 245 255 10.1007/s10495-019-01532-030929105 Search in Google Scholar

[60] Sheng W., Chen C., Dong M., Zhou J., Liu Q., Dong Q., Li F.: Over-expression of calreticulin contributes to the development and progression of pancreatic cancer. J. Cell. Physiol., 2014; 229: 887–897 ShengW. ChenC. DongM. ZhouJ. LiuQ. DongQ. LiF. Over-expression of calreticulin contributes to the development and progression of pancreatic cancer J. Cell. Physiol. 2014 229 887 897 10.1002/jcp.2451924264800 Search in Google Scholar

[61] Shide K., Kameda T., Yamaji T., Sekine M., Inada N., Kamiunten A., Akizuki K., Nakamura K., Hidaka T., Kubuki Y., Shimoda H., Kitanaka A., Honda A., Sawaguchi A., Abe H., et al.: Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib. Leukemia, 2017; 31: 1136–1144 ShideK. KamedaT. YamajiT. SekineM. InadaN. KamiuntenA. AkizukiK. NakamuraK. HidakaT. KubukiY. ShimodaH. KitanakaA. HondaA. SawaguchiA. AbeH. Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib Leukemia 2017 31 1136 1144 10.1038/leu.2016.308542079327807369 Search in Google Scholar

[62] Shivarov V., Ivanova M., Tiu R.V.: Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca²⁺: Some mechanistic and therapeutic implications. Blood Cancer J., 2014; 4: e185 ShivarovV. IvanovaM. TiuR.V. Mutated calreticulin retains structurally disordered C terminus that cannot bind Ca²⁺: Some mechanistic and therapeutic implications Blood Cancer J. 2014 4 e185 10.1038/bcj.2014.7394466424562385 Search in Google Scholar

[63] Stanley R.F., Steidl U.: Molecular mechanism of mutant CALR-mediated transformation. Cancer Discov., 2016; 6: 344–346 StanleyR.F. SteidlU. Molecular mechanism of mutant CALR-mediated transformation Cancer Discov. 2016 6 344 346 10.1158/2159-8290.CD-16-0238483298127045016 Search in Google Scholar

[64] Szuber N., Lamontagne B., Busque L.: Novel germline mutations in the calreticulin gene: Implications for the diagnosis of myeloproliferative neoplasms. J. Clin. Pathol., 2016; 69: 1033–1036 SzuberN. LamontagneB. BusqueL. Novel germline mutations in the calreticulin gene: Implications for the diagnosis of myeloproliferative neoplasms J. Clin. Pathol. 2016 69 1033 1036 10.1136/jclinpath-2016-20394027466382 Search in Google Scholar

[65] Tefferi A., Wassie E.A., Guglielmelli P., Gangat N., Belachew A.A., Lasho T.L., Finke C., Ketterling R.P., Hanson C.A., Pardanani A., Wolanskyj A.P., Maffioli M., Casalone R., Pacilli A., Vannucchi A.M., et al.: Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am. J. Hematol., 2014; 89: E121–E124 TefferiA. WassieE.A. GuglielmelliP. GangatN. BelachewA.A. LashoT.L. FinkeC. KetterlingR.P. HansonC.A. PardananiA. WolanskyjA.P. MaffioliM. CasaloneR. PacilliA. VannucchiA.M. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients Am. J. Hematol. 2014 89 E121 E124 10.1002/ajh.2374324753125 Search in Google Scholar

[66] Truxova I., Kasikova L., Salek C., Hensler M., Lysak D., Holicek P., Bilkova P., Holubova M., Chen X., Mikyskova R., Reinis M., Kovar M., Tomalova B., Kline J.P., Galluzzi L., et al.: Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica, 2020; 105: 1868–1878 TruxovaI. KasikovaL. SalekC. HenslerM. LysakD. HolicekP. BilkovaP. HolubovaM. ChenX. MikyskovaR. ReinisM. KovarM. TomalovaB. KlineJ.P. GalluzziL. Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients Haematologica 2020 105 1868 1878 10.3324/haematol.2019.223933732763831582537 Search in Google Scholar

[67] Vainchenker W., Kralovics R.: Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood, 2017; 129: 667–679 VainchenkerW. KralovicsR. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms Blood 2017 129 667 679 10.1182/blood-2016-10-69594028028029 Search in Google Scholar

[68] Vaksman O., Davidson B., Tropé C., Reich R.: Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum. Pathol., 2013; 44: 2677–2683 VaksmanO. DavidsonB. TropéC. ReichR. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases Hum. Pathol. 2013 44 2677 2683 10.1016/j.humpath.2013.07.00924060004 Search in Google Scholar

[69] Varricchio L., Falchi M., Dall’Ora M., De Benedittis C., Ruggeri A., Uversky V.N., Migliaccio A.R.: Calreticulin: Challenges posed by the intrinsically disordered nature of calreticulin to the study of its function. Front. Cell Dev. Biol., 2017; 5: 96 VarricchioL. FalchiM. Dall’OraM. De BenedittisC. RuggeriA. UverskyV.N. MigliaccioA.R. Calreticulin: Challenges posed by the intrinsically disordered nature of calreticulin to the study of its function Front. Cell Dev. Biol. 2017 5 96 10.3389/fcell.2017.00096570371529218307 Search in Google Scholar

[70] Wijeyesakere S.J., Bedi S.K., Huynh D., Raghavan M.: The C-terminal acidic region of calreticulin mediates phosphatidylserine binding and apoptotic cell phagocytosis. J. Immunol., 2016; 196: 3896–3909 WijeyesakereS.J. BediS.K. HuynhD. RaghavanM. The C-terminal acidic region of calreticulin mediates phosphatidylserine binding and apoptotic cell phagocytosis J. Immunol. 2016 196 3896 3909 10.4049/jimmunol.1502122522254927036911 Search in Google Scholar

[71] Wijeyesakere S.J., Gagnon J.K., Arora K., Brooks C.L.3rd, Raghavan M.: Regulation of calreticulin-major histocompatibility complex (MHC) class I interactions by ATP. Proc. Natl. Acad. Sci. USA, 2015; 112: E5608–E5617 WijeyesakereS.J. GagnonJ.K. AroraK. BrooksC.L.3rd RaghavanM. Regulation of calreticulin-major histocompatibility complex (MHC) class I interactions by ATP Proc. Natl. Acad. Sci. USA 2015 112 E5608 E5617 10.1073/pnas.1510132112461159826420867 Search in Google Scholar

[72] Yue X., Wang H., Zhao F., Liu S., Wu J., Ren W., Zhu Y.: Hepatitis B virus-induced calreticulin protein is involved in IFN resistance. J. Immunol., 2012; 189: 279–286 YueX. WangH. ZhaoF. LiuS. WuJ. RenW. ZhuY. Hepatitis B virus-induced calreticulin protein is involved in IFN resistance J. Immunol. 2012 189 279 286 10.4049/jimmunol.110340522661095 Search in Google Scholar

[73] Zamanian M., Veerakumarasivam A., Abdullah S., Rosli R.: Calreticulin and cancer. Pathol. Oncol. Res., 2013; 19: 149–154 ZamanianM. VeerakumarasivamA. AbdullahS. RosliR. Calreticulin and cancer Pathol. Oncol. Res. 2013 19 149 154 10.1007/s12253-012-9600-223392843 Search in Google Scholar